尼妥珠单抗联合放化疗治疗宫颈癌的临床价值研讨
Clinical Value Discussion of Nimotuzumab Combined with Radiotherapy and Chemotherapy in Treatment of Cervical Cancer
王雪梅1
作者信息
- 1. 开远市人民医院,云南 红河 661699
- 折叠
摘要
目的 研究尼妥珠单抗联合放化疗治疗宫颈癌的临床价值.方法 选取2022年本院收治的80例宫颈癌患者为研究对象,随机将其分为对照组和研究组,每组40例.对照组采取同步放化疗治疗,研究组在对照组的基础上联合尼妥珠单抗治疗,对比分析不同方式的治疗效果.结果 治疗后,研究组治疗有效率高于对照组(P<0.05);研究组B7-H4、PCNA、HIF-1ɑ低于对照组,FH1T、PTEN、STC1高于对照组(P<0.05);两组毒副作用发生率相比,无显著差异(P>0.05).结论 运用同步放化疗联合尼妥珠单抗治疗宫颈癌,可改善病灶癌细胞增殖基因mRNA表达量,且治疗的安全性较高,此方案建议推广运用.
Abstract
Objective To study the clinical value of nimotuzumab and chemoradiotherapy in cervical cancer.Methods 80 cervical cancer patients admitted to our hospital in 2022 were selected as the study subjects and randomly divided into control group and study group,with 40 patients in each group.The control group adopted concurrent chemoradiotherapy,and the study group combined nytuzumab on the basis of the control group,and compared the treatment effects of different methods.Results After treatment,the treatment response rate was higher than the control group(P<0.05);the study group B7-H4,PCNA,HIF-1 ɑ was lower than the control group;FH 1 T,PTEN,and STC 1 were higher than the control group(P<0.05);the study group had high probability of toxicity and side effects,but P>0.05.Conclusion The use of concurrent radiotherapy and chemotherapy combined with nimotuzumab to treat cervical cancer can improve the mRNA expression of proliferation genes of focal cancer cells,and the safety of treatment is high.This scheme is suggested to be applied.
关键词
尼妥珠单抗/放化疗/宫颈癌/治疗效果/毒副作用Key words
Nimotuzumab/Radiochemotherapy/Cervical cancer/Curative effect/Toxic side effect引用本文复制引用
出版年
2024
NETL
NSTL
万方数据